Global pharmaceutical company Pfizer (NYSE: PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.

Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands like Eliquis and Padcev, noting that commercial teams “performed with excellence and precision” across major therapeutic areas.

Looking ahead, Pfizer’s guidance is anchored by expectations for steady growth in key therapeutic franchises and a disciplined approach to cost management. Interim CFO Cecile Guegan stated the company is “well positioned to return to growth from 2029 onward,” underpinned by ongoing investment in research and development, especially in obesity and oncology. Management also highlighted the anticipated impact of new products advancing through late-stage trials and a commitment to capital allocation that preserves the dividend and enables reinvestment. CEO Bourla reinforced that artificial intelligence and productivity enhancement initiatives are expected to create operational efficiencies and support the next wave of innovation.

Key Insights from Management’s Remarks

Management credited product innovation, successful integration of recent acquisitions, and cost control initiatives as central to Pfizer’s Q2 performance and its outlook for the remainder of the year.

• Acquisitions Drive Growth: Revenue from launched and acquired products grew 18% operationally, with the legacy Seagen portfolio delivering a 21% year-over-year increase in the U.S. (excluding a one-time stocking benefit), and excluding this one-time impact, the growth rate for acquired products was 27%. This supports the strategy to expand in oncology and neurology. The Biohaven transaction also contributed, with NURTEC continuing to lead its class in migraine treatment.
• Obesity Pipeline Advances: The Metsera acquisition enabled progress in obesity therapies, with berobenatide—a potential first-in-class, monthly GLP-1 receptor agonist—showing Phase IIb data supporting robust weight loss. Management aims for a first approval in 2028 and is advancing ten Phase III studies this year, targeting a market expected to reach $150 billion.
• R&D Productivity and Milestones: Pfizer reported three regulatory approvals, six key data readouts, and eight pivotal study starts in the first half of the year. The company’s oncology pipeline, including late-stage studies in core tumor areas, is a focus area for future growth.
• Cost Discipline and Efficiency: Ongoing cost realignment and manufacturing optimization programs are expected to generate $9.7 billion in net savings by 2029. The implementation of artificial intelligence is already yielding benefits in manufacturing and commercial execution.
• Portfolio Diversification: Management cited strong non-COVID product performance, with contributions from Eliquis, Padcev, and Vyndaqel. This diversification helped offset the decline in COVID-related revenues and provided resilience against upcoming loss of exclusivity events.

Drivers of Future Performance

Pfizer’s forward outlook centers on late-stage product launches, disciplined capital allocation, and productivity improvements amid ongoing headwinds from COVID product demand and patent expirations.

• Late-Stage Pipeline Readouts: The company is counting on key clinical milestones, including pivotal data for oncology assets like mevrometostat in prostate cancer and expansion indications for Padcev, to drive the next phase of revenue growth. Management views the MEVPRO-1 study readout as a potential breakthrough opportunity, with global commercial potential if successful.
• Obesity and Metabolic Disease Expansion: Management is prioritizing the obesity market, advancing berobenatide and amylin analog combinations through late-stage trials. They expect these assets to provide differentiated efficacy and dosing convenience, with initial approvals targeted for 2028 and broader data readouts in 2027.
• Cost Initiatives and Dividend Commitment: Ongoing cost savings programs and technology-driven efficiency gains are intended to protect margins and free up cash for R&D and shareholder returns. CEO Bourla reiterated that maintaining and eventually growing the dividend remains a top priority, even through the upcoming loss of exclusivity period.

Catalysts in Upcoming Quarters

In the next several quarters, the StockStory team will be watching (1) clinical readouts for late-stage oncology and obesity programs, (2) the pace of cost savings realization and manufacturing optimization, and (3) the expansion of commercial uptake for recently acquired brands and new product launches. Progress on artificial intelligence integration and further regulatory milestones will also be important indicators of execution.

Pfizer currently trades at $25.33, up from $25.05 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.